Viatris Inc. (Nasdaq: VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company’s Executive Leadership Team.
Varghese is an accomplished healthcare leader with more than 20 years of strategy, operations and corporate development experience. He brings broad experience leading growth initiatives and strategic transformations in diversified multi-national healthcare companies.
Prior to joining Viatris, Varghese was President and Chief Operating Officer at Venus Concept, an innovative global medical aesthetic technology company. He previously served as Senior Vice President, Strategy & Operations at HLS Therapeutics. He also held multiple roles at Endo International, including Executive Vice President, Corporate Development & Strategy and President, International Pharmaceuticals, several roles of increasing responsibility at Valeant Pharmaceuticals and Bausch & Lomb, and worked in corporate development at Biovail Corporation. Varghese earned a bachelor’s degree and a Ph.D. in medical biophysics from the University of Western Ontario in Ontario, Canada, and is a Chartered Financial Analyst.
“We are excited to welcome Hemanth to Viatris in the role of Chief Strategy Officer,” said Scott A. Smith, CEO, Viatris. “Hemanth adds another valuable perspective to our Executive Leadership Team. I believe his skills and expertise will be integral as we continue to shape our company for growth in 2026 and beyond.”
“I am honored to be joining Viatris at such a transformative time for the company,” said Varghese. “I’m looking forward to partnering with Scott, the Executive Leadership Team and others across the organization as we continue to build a strong company for the future.”
About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life’s moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter).
